Old Web
English
Sign In
Acemap
>
authorDetail
>
Brad Lanoue
Brad Lanoue
Novartis
Medicine
Hormone receptor
Oncology
Internal medicine
Pathology
4
Papers
10
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer.
2021
Cancer management and research
Peter A. Fasching
Thomas E. Delea
Yen-Shen Lu
Richard de Boer
Sara A. Hurvitz
Aaron Moynahan
David Chandiwana
Brad Lanoue
H Hu
A. Thuerigen
Joyce OShaughnessy
Show All
Source
Cite
Save
Citations (0)
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7):
2020
Therapeutic Advances in Medical Oncology
Nadia Harbeck
F Franke
Rafael Villanueva Vázquez
Yen-Shen Lu
Debu Tripathy
Louis W.C. Chow
Govind Babu
Young-Hyuck Im
D. Chandiwana
Anil Gaur
Brad Lanoue
Karen Rodriguez-Lorenc
Aditya Bardia
Show All
Source
Cite
Save
Citations (9)
Real-world dosing patterns of everolimus-based lines of therapy among post-menopausal women with hormone receptor-positive and human epidermal growth factor receptor-negative (HR+/HER2-) metastatic breast cancer (mBC).
2017
Journal of Clinical Oncology
Nicole Princic
Matthew Brouillette
Derek H. Tang
Chinjune Lin
Brad Lanoue
Victoria Barghout
Show All
Source
Cite
Save
Citations (0)
Analysis of real world patient compliance to everolimus-based therapy among post-menopausal women with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC).
2017
Journal of Clinical Oncology
Nicole Princic
Matthew Brouillette
Derek H. Tang
Chinjune Lin
Brad Lanoue
Victoria Barghout
Show All
Source
Cite
Save
Citations (1)
1